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Abstract 
Objective. The aim of this study was to investigate the association of different physical fitness levels 
[assessed by the maximal oxygen uptake (VO2max) test] with cardiovascular disease (CVD) risk 
factors in patients with RA.  
Methods. A total of 150 RA patients were assessed for cardiorespiratory fitness with a VO2max test 
and, based on this, were split in three groups using the 33rd (18.1 ml/kg/min) and 66th (22.4 
ml/kg/min) centiles. Classical and novel CVD risk factors [blood pressure, body fat, insulin resistance, 
cholesterol, triglycerides, high-density lipoprotein (HDL), physical activity, CRP, fibrinogen and white 
cell count], 10-year CVD risk, disease activity (DAS28) and severity (HAQ) were assessed in all cases.  
Results. Mean VO2max for all RA patients was 20.9 (S.D. 5.7) ml/kg/min. The 10-year CVD risk (P = 
0.003), systolic blood pressure (P = 0.039), HDL (P = 0.017), insulin resistance and body fat (both at 
P<0.001), CRP (P = 0.005), white blood cell count (P = 0.015) and fibrinogen (P<0.001) were 
significantly different between the VO2max tertiles favouring the group with the higher VO2max 
levels. In multivariate analyses of variance, VO2max was significantly associated with body fat 
(P<0.001), HDL (P = 0.007), insulin resistance (P<0.003) and 10-year CVD risk (P<0.001), even after 
adjustment for DAS28, HAQ and physical activity.  
Conclusion. VO2max levels are alarmingly low in RA patients. Higher levels of VO2max are 
associated with a better cardiovascular profile in this population. Future studies need to focus on 
developing effective behavioural interventions to improve cardiorespiratory fitness in RA.  
Key words: exercise, physical activity, cardiorespiratory fitness, cardiovascular disease, 
inflammation, rheumatoid arthritis. 
Rheumatology key messages 
 Cardiorespiratory fitness is alarmingly low in RA patients. 
 Cardiovascular profile and 10-year cardiovascular disease risk are both deteriorated in RA 
patients with low fitness levels. 
 Cardiorespiratory fitness may be a good surrogate cardiovascular disease marker in RA. 
Introduction 
RA is associated with an increased risk of cardiovascular disease (CVD) [1], attributed both to the 
deleterious effects of inflammation on the vasculature and to the increased prevalence of traditional 
CVD risk factors [2-5]. Increased physical activity and/or exercise may be associated with an 
improved CVD risk profile in both healthy and diseased populations; this is indicated by the robust 
inverse relationship of CVD morbidity and mortality with cardiorespiratory fitness, as measured by 
the gold standard method, the maximal oxygen uptake (VO2max) test [6]. Patients with RA have 
significantly lower levels of VO2max compared with healthy counterparts [7], but the association of 
VO2max with CVD risk has never been investigated in this population. The aim of the present cross-
sectional study was to investigate the association of VO2max with both traditional and novel CVD 
risk factors and 10-year CVD risk in a well-characterized population of patients with RA. 
Methods 
Participants 
One hundred and fifty patients were recruited from the Dudley Group of Hospitals NHS Foundation 
Trust, UK. The study was approved by the Birmingham East, North and Solihull Research Ethics 
Committee, and volunteers signed informed consent after we provided a detailed verbal and written 
description of the procedures involved, according to the Declaration of Helsinki. Patients’ records 
were reviewed before requesting participation. Inclusion criteria were: fulfilling the ACR RA criteria 
and being on stable treatment for at least 3 months. Exclusion criteria were: previous/present CVD 
(e.g. cardiomyopathies, arrhythmias), cerebrovascular disease, diabetes, restrictive/ obstructive lung 
disease, known malignancy, pregnancy, current infection, hyper- or hypothyroidism, recent joint 
surgery (preceding 6 months), amputation and functional comorbidities incompatible with VO2max 
testing. 
Procedures 
Patients visited our laboratory after a 12-h overnight fast for collection of blood samples and 
recording of demographic, anthropometric and disease-related characteristics: standing height was 
measured with a Seca Stadiometer, body mass and composition via bioelectrical impedance (Tanita 
BC418-MA, Japan), disease activity via ESR, CRP and the 28 joint DAS DAS28, and disease severity via 
the Stanford HAQ. Classical and novel CVD risk profile included: triglycerides, total cholesterol, 
highdensity lipoprotein (HDL), low-density lipoprotein (LDL) (Vitros 5.1, USA), physical activity 
(International Physical Activity Questionnaire), glucose and insulin (Immunolite 2000 Analyser, USA) 
[from which the homeostasis model assessment (HOMA) was calculated], blood pressure, family 
history, smoking, CRP (Vitros 5.1 FS, USA), haemoglobin and white cell count (ADVIA 120, Germany) 
and fibrinogen (IL Futura Advance analyser, UK). Ten-year CVD risk was calculated using the 
Framingham score.  
Participants returned within 3 days to perform an individualized VO2max test protocol with 
electrocardiography (after taking into account their physical abilities and the American Heart 
Association guidelines) using a previously published protocol [8] and specific contraindications for 
terminating the test [9]. The VO2max test was performed on a treadmill using a calibrated breath-
by-breath system (Metalyzer 3B, Cortex, Germany). Based on the results of the VO2max test, 
participants were divided into three groups, using the 33rd (18.1 ml/kg/min) and 66th (22.4 
ml/kg/min) centiles [10]. To determine the number of participants needed per group, we used RA [8] 
and age-matched normal population VO2max data, and calculated that 44 patients were needed per 
group (90% power and 5% alpha error level). To account for potential dropout, we recruited 150 
patients (i.e. 50 per group). Given the relevant VO2max data from the general population [9], these 
groups reflected unfit vs moderately unfit vs average fitness groups, respectively.  
Statistical analyses  
Kolmogorov_Smirnov tests were performed to investigate the distribution of all variables. 
Accordingly, normally distributed variables are reported as mean (S.D.), whereas non-normally 
distributed variables as median [interquartile range (IQR)]. Chi-square analyses were conducted to 
investigate differences amongst the VO2max tertiles for categorical variables (e.g. gender and 
medication). One-way analyses of variance with Bonferroni correction for adjusting the number of 
multiple comparisons or Kruskal_Wallis tests were utilized, according to distribution, to investigate 
differences between VO2max tertiles. After controlling for age, gender and physical activity, 
multivariate analyses of variance with Sidak correction were initially utilized to investigate the 
association of VO2max levels (as a categorical variable for the three groups) with CVD risk factors. 
Thereafter, disease activity and severity variables were also utilized in the same models to 
investigate whether the association of VO2max with CVD factors and 10-year CVD risk persisted. For 
the multivariate analyses of variances, log transformations were conducted on all the variables that 
were not normally distributed. The adjusted mean differences (with 95% CI) were also reported for 
the variables that were significantly different. The level of significance was set at P<0.05. 
Results 
Of the 150 patients who agreed to participate, 6 did not attend. Mean VO2max for the entire cohort 
was 20.9 (S.D.5.7) ml/kg/min, and it was significantly different between the tertiles, that is, unfit: 
15.4 (S.D. 1.9) vs moderately unfit: 20.2 (S.D. 1.3) vs average: 27.1 (S.D. 4.7) ml/kg/min (P<0.001). 
Significant differences were detected between the tertiles in age (Table 1, P = 0.035) but not gender 
(Table 1, P = 0.095) or physical activity (Table 2, P = 0.051). The anthropometric and disease-related 
characteristics of the three RA groups appear in Table 1.  
Table 1. Anthropometric and disease-related characteristics the total population and fitness 
subgroups  
Characteristics Total RA  
(n = 144) 
Unfit  
(n = 47) 
Moderately unfit 
(n = 48) 
Average fitness 
(n = 49) 
P-value 
VO2max, mean 
(S.D.), ml/kg/min 
20.9 (5.7) 15.4 (1.9)** 20.2 (1.3)** 27.1 (4.7) <0.001 
Age, mean (S.D.), 
years 
54.4 (11.7) 54.7 (13.4) 57.3 (10.3)* 51.2 (10.6) 0.035 
Gender: females, n 101 37 35 29 0.095 
Anthropometric, 
median (IQR) 
     
Height, cm .66 (1.59-1.71) 11.66 (1.59-1.71) 1.64 (1.59-1.73) 1.66 (1.61-1.72) 0.777 
Weight, kg 76.8 (65.5-90.0) 86.3 (70.5-97.7)** 77.5 (70.5-86.8)* 69.2 (59.3-82.0) <0.001 
Fat-free mass, kg 49.0 (42.0-58.0) 49.0 (42.2-59.7) 47.0 (42.0-58.0) 49.0 (42.0-60.0) 0.944 
RA characteristics, 
median (IQR) 
     
Disease duration, 
years 
6.0 (3.0-10.0) 5.0 (2.0-6.5) 7.0 (4.0-14.5)* 5.0 (3.0-7.5) 0.046 
DAS28 3.2 (2.3-4.5) 3.2 (2.1-4.6) 3.0 (2.3-4.0) 3.3 (2.3-4.5) 0.817 
ESR, mm 1st h 11.0 (5.0-21.0) 19.0 (12.0-32.7)** 10.0 (7.0-21.5)* 5.0 (2.0-10.2) <0.001 
HAQ 0.58 (0.13-1.12) 0.79 (0.17-1.13) 0.52 (0.16-1.21) 0.35 (0.1-1.0) 0.617 
Medication, n (%)      
DMARDs 73 (50) 24 (33) 28 (38) 21 (29) 0.414 
Anti-TNFa 22 (15) 10 (45) 5 (23) 7 (32) 0.350 
NSAIDs 50 (35) 17 (34) 15 (30) 18 (36) 0.948 
Analgesics 57 (40) 20 (35) 18 (32) 19 (33) 0.709 
P = differences between groups using either ANOVA or Kruskal_Wallis test. Normally distributed 
variables are reported as mean (S.D.) and non-normally distributed variables as median (IQR). 
Significantly different from the Average fitness group: **P<0.001 and *P<0.05. Significant values are 
highlighted in bold. VO2max: maximal oxygen uptake; IQR: interquartile range; DAS28: DAS for 28 
joints. 
Associations between cardiovascular profile and VO2max 
Significant differences between the three groups were detected in systolic blood pressure, HDL, 
insulin resistance and body fat, CRP, fibrinogen and white blood cell count, as well as 10-year CVD 
risk (Table 2).  
Table 2. Classical CVD risk factors and 10-year CVD risk of the total population and fitness groups 
studied 
Risk Factors Total RA 
(n = 144) 
Unfit 
(n = 47) 
Moderately 
unfit (n = 48) 
Average fitness 
(n = 49) 
P-value 
Classical risk 
factors, mean (S.D.) 
     
SBP, mmHg 132.6 
(15.9) 
134.4 (15.0) 135.6 (17.0)* 127.9 (14.7) 0.039 
DBP, mmHg 81.0 (9.8) 80.4 (10.3) 82.8 (10.4) 79.6 (8.5) 0.4 
Triglycerides, 
median (IQR), 
mmol/l 
1.1 (0.8-
1.6) 
1.1 (0.8-2.1) 1.1 (0.0-1.7) 1.1 (0.8-1.4) 0.46 
Cholesterol, mean 
(S.D.), mmol/l 
5.0 (1.0) 5.1 (1.1) 5.1 (1.1) 5.0 (0.9) 0.916 
HDL, median (IQR), 
mmol/l 
1.4 (1.1-
1.7) 
1.2 (1.1-1.6)* 1.3 (1.2-1.6) 1.5 (1.2-1.8) 0.017 
LDL, median (IQR), 
mmol/l 
3.1 (2.5-
3.6) 
2.7 (2.4-3.7) 3.1 (2.5-3.6) 3.1 (2.6-3.5) 0.847 
Glucose, median 
(IQR), mmol/l 
4.6 (4.4-
5.0) 
4.6 (4.3-5.1) 4.7 (4.3-5.0) 4.6 (4.4-5.0) 0.772 
HOMA, median 
(IQR), mmol/l 
1.5 (0.9-
2.3) 
2.0 (1.4-2.4)* 1.5 (1.2-2.1)* 0.9 (0.6-1.7) <0.001 
BMI, median (IQR), 
kg/m2 
27.8 
(24.2-
31.5) 
30.0 (26.0-35.0)** 27.9 (25.3-
31.0)* 
24.5 (22.1-27.8) <0.001 
Fat mass, median 
(IQR), % 
35.0 
(30.0-
42.0) 
41.0 (34.8-46.2)** 38.0 (32.2-
42.7)** 
30.0 (25.5-33.9) <0.001 
Physical activity, 3109.0 2102.5 2830.5 3549.0 0.051 
Metabolic 
Equivalent 
(1085.0-
5812.5) 
(925.5-4447.5) (946.5-6018.7) (1782.0-9759.0)  
 
Task_min/week, 
median (IQR) 
     
Smoking, n 17 6 4 7 0.912 
Family history of 
CVD, n 
62 23 20 19 0.995 
Novel risk factors      
CRP, median (IQR), 
mg/l 
3.6 (2.6-
8.6) 
7.3 (3.0-10.7)* 4.5 (2.7-9.8)* 3.0 (1.7-4.5) 0.005 
vWF, median (IQR), 
IU/dl 
 
136 (108-
181) 
138 (120-180) 143 (103-193) 129.0 (88-170) 0.329 
White cell count, 
mean (S.D.), _109/l 
6.7 (2.1) 7.3 (2.4)* 6.8 (1.9) 6.0 (1.8) 0.015 
Haemoglobin, 
mean (S.D.), g/dl 
13.3 (1.2) 13.1 (1.0)* 13.4 (1.2) 13.4 (1.4) 0.519 
10 year CVD risk, % 7.0 (3.0-
13.0) 
8.0 (4.0-15.2) 7.0 (4.0-12.9) 4.0 (2.0-7.0) 0.003 
P = differences between groups using either ANOVA or Kruskal_Wallis test. Normally distributed 
variables are reported as mean (S.D.) and non-normally distributed variables as median (IQR). 
Significantly different from the Average fitness group: **P<0.001 and *P<0.05. Significant values are 
highlighted in bold. SBP: systolic blood pressure; DBP: diastolic blood pressure; IQR: interquartile 
range; HDL: high density lipoprotein; LDL: low density lipoprotein; HOMA: homeostatic model 
assessment; CVD: cardiovascular disease; vWF: von Willebrand factor. 
Adjusted associations between cardiovascular profile and VO2max  
Classical CVD risk factors: after correction for age, gender and physical activity, VO2max levels were 
significantly associated with body fat (F1,107 = 16.7, P<0.001), HOMA (F1,107 = 6.0, P = 0.003) and 
HDL (F1,107 = 5.3, P = 0.007), but not systolic blood pressure (P>0.05). After further adjustment for 
DAS28 and HAQ, VO2max was significantly associated with: (i) body fat (F1,107 = 15.7, P<0.001), 
which was related to the differences reported between the average vs the unfit groups [mean 
difference 10.9% (95% CI 6.1%, 15.7%), P<0.001] and average vs moderately unfit groups [mean 
difference 6.8% (95% CI 2.2%, 11.3%), P = 0.001] and (ii) HOMA (F1,107 = 4.4, P = 0.016) and HDL 
(F1,107 = 5.6, P = 0.005), which was related to the differences that were observed in the average vs 
the unfit group [mean difference HOMA 0.52 (95% CI 0.09, 0.95), P = 0.012 and HDL 0.23 (95% CI 
0.05, 0.41) mmol/ l, P = 0.007]. 
Novel CVD risk factors: after correction for age, gender and physical activity, VO2max levels 
revealed significant associations with CRP (F1,109 = 3.8, P = 0.025) and fibrinogen (F1,109 = 18.5, 
P<0.001), but not white blood cells (P = 0.087). For CRP, this association was related to the 
differences between the average vs the unfit group [mean difference 0.78 (95% CI 0.09, 1.47) mg/l, P 
= 0.021]. Further correction for DAS28 and HAQ did not eliminate the significant association 
observed between VO2max levels and fibrinogen (P<0.001): these associations were related to the 
differences between the unfit vs the average groups [mean difference 1.2 (95% CI 0.64, 1.80) g/dl, 
P<0.001] as well as the moderately unfit vs the average groups [mean difference 0.64 (95% CI 0.06, 
1.22) g/ dl, P = 0.024]. 
Ten-year CVD risk: after adjustment for age, gender and physical activity, the levels of 
VO2max were significantly associated with the 10-year CVD risk (F1,123 = 11.2, P<0.001), and further 
correction for DAS28 and HAQ in this model did not alter this association (F1,123 = 10.8, P<0.001). 
This was related to the differences that were detected between the average vs the unfit groups 
[mean difference 1.23 (95% CI 0.58, 1.88) years, P<0.001] as well as the average vs the moderately 
unfit patients [mean difference 0.81 (95% CI 0.18, 1.45) years, P = 0.007]. 
Discussion 
RA patients with higher VO2max had a better CVD risk profile and a lower 10-year CVD risk 
compared with those with lower VO2max levels. Substantial evidence demonstrates a strong inverse 
association between CVD morbidity and mortality and VO2max [11, 12], highlighting the important 
role of fitness in health and longevity. RA patients repeatedly demonstrate significantly lower 
VO2max levels compared with healthy counterparts, most likely related to their low levels of 
physical activity [7, 13] and increased disease activity/severity; for example, a fit RA patient may stop 
the test, potentially because of disease-related pain and physical dysfunction and not because of 
cardiorespiratory limitations. The low overall VO2max levels observed in this study is an alarming 
finding that could be linked with the increased incidence of CVD-related death in RA; however, 
appropriate longitudinal studies are necessary to confirm this. Our results suggest significant 
differences between RA patients classified according to fitness level with respect to a variety of 
classic and novel CVD risk factors, as well as their 10-year CVD risk. As such, it seems reasonable to 
suggest that increased cardiorespiratory fitness may provide a measure of protection against CVDs 
in this population, which is similar to what is seen in the normal population [14, 15] and in other 
rheumatic diseases [16].  
Further analyses have demonstrated that, after controlling for disease activity and severity, 
VO2max levels are significantly associated with body fat, HDL and insulin resistance. RA patients 
experience a condition termed rheumatoid cachexia, which is characterized by a significant increase 
in adiposity and decreased muscle mass; as such, at the same weight a patient with RA may have an 
altered body composition compared with a normal healthy individual that favours an inferior 
cardiovascular profile [17]. This condition seems to be mediated by both inflammation and physical 
inactivity [17]. Studies in RA have previously shown that obesity is associated with both low HDL and 
insulin resistance [18]. Moreover, inflammation, which is overexpressed in both obesity and RA, 
affects glucose metabolism and the enzymes fundamental to HDL metabolism, promoting the 
development of insulin resistance and atherosclerosis [19]. The interplay of these factors with 
physical inactivity may in part explain the increased incidence of CVD in RA.  
Exercise is the predominant intervention for increasing VO2max. Even in a disease such as 
RA, which is characterized by significant disability, pain and fatigue, exercise is recommended; in 
fact, it can even ameliorate disease-related symptoms [20] and the calculated risk for CVD. 
Therefore, RA patients can and should exercise, but they consistently report lower levels of fitness 
compared with the healthy population [7, 16]. The effects of exercise on improving disease activity 
and cardiovascular risk factors have also been shown in axial SpA, another chronic inflammatory 
joint disease [21]. Research investigating ways of increasing and maintaining physical activity and 
reducing sedentary behaviour in RA patients is necessary.  
This study is limited by not evaluating VO2max levels of an equivalent age- and gender-
matched population, its cross-sectional design and the non-inclusion of patients with pulmonary 
fibrosis/nodules or other significant extraarticular features (as well as by not keeping detailed 
records of non-included patients). Patients with poor mobility were also excluded, possibly 
introducing a positive bias in the present study. This would suggest that we have selected the fittest 
RA patients herein; even so, we demonstrated that their VO2max levels were alarmingly low. 
Nevertheless, this is the first study that has explored the associations between VO2max and CVD risk 
factors with such a large sample of RA patients using appropriate power calculations and adjustment 
for several potential confounders. We conclude that, overall, VO2max levels are low in both female 
and male RA patients, and that lower VO2max levels are associated with inferior CVD profile and 
higher 10-year CVD event risk.  
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